Teva Pharmaceutical Industries has introduced its tolterodine tartrate extended-release capsules in the 2-mg and 4-mg strengths to address overactive bladder. The drug is a generic equivalent of Pfizer's Detrol LA.
Mylan and unit Mylan Pharmaceuticals settled a patent-infringement lawsuit with Pfizer, Pfizer Health and Pharmacia & Upjohn regarding Mylan Pharmaceuticals' abbreviated new-drug application for extended-release tolterodine tartrate, a treatment for overactive bladder. The drug is a generic version of Pfizer's Detrol LA. The agreement closes pending litigation and authorizes Mylan Pharmaceuticals to sell the generic on or before Jan. 1, 2014, under limited circumstances and March 1, 2014, subject to FDA approval.
Pfizer settled a patent-infringement lawsuit with Impax Laboratories regarding the former's overactive bladder treatment Detrol LA, or extended-release tolterodine tartrate. The accord settles litigation with Impax but not with Mylan Pharmaceuticals, which also sought marketing approval of a generic version of Detrol LA.